BRAF and melanoma: In tumor types with sufficient validation data on immunohistochemistry and sequencing available, i.e. melanoma, colorectal and thyroid carcinoma and pleomorphic xanthoastrocytomas, VE-1 immunostaining might be sufficient to indicate BRAF V600E targeted therapy.